Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 2,560 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 2,560 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Disc Medicine Stock Down 4.1 %

Shares of IRON opened at $30.52 on Tuesday. The company has a market cap of $736.75 million, a PE ratio of -8.74 and a beta of 0.18. The business has a fifty day moving average of $57.94 and a 200 day moving average of $55.86. Disc Medicine, Inc. has a 52-week low of $21.70 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). As a group, research analysts anticipate that Disc Medicine, Inc. will post -4.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Stifel Nicolaus increased their target price on Disc Medicine from $71.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Morgan Stanley lowered their target price on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research report on Monday, April 1st. BMO Capital Markets lowered their target price on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday, April 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research report on Wednesday, December 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Disc Medicine currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.29.

Institutional Trading of Disc Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its stake in Disc Medicine by 12.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,308,405 shares of the company’s stock worth $61,469,000 after purchasing an additional 145,781 shares during the period. Perceptive Advisors LLC increased its stake in shares of Disc Medicine by 14.2% during the fourth quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock valued at $59,091,000 after buying an additional 127,404 shares during the period. Frazier Life Sciences Management L.P. increased its stake in shares of Disc Medicine by 19.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company’s stock valued at $45,342,000 after buying an additional 130,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Disc Medicine by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 764,544 shares of the company’s stock valued at $44,160,000 after buying an additional 99,092 shares during the period. Finally, Citadel Advisors LLC increased its stake in shares of Disc Medicine by 280.4% during the second quarter. Citadel Advisors LLC now owns 651,320 shares of the company’s stock valued at $28,919,000 after buying an additional 480,082 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.